Headlands Technologies LLC Cuts Holdings in LivaNova PLC $LIVN

Key Points

• Headlands Technologies LLC significantly reduced its holdings in LivaNova PLC by 92.8%, owning only 932 shares valued at $37,000 after selling 12,039 shares in the first quarter.
• In recent analyst reports, LivaNova received upgrades, including a shift from a "buy" to a "strong-buy" rating, and a current consensus price target of $59.29.
• LivaNova reported a quarterly earnings per share (EPS) of $1.05, exceeding analyst expectations of $0.84 and showing a 10.6% year-over-year revenue increase to $352.50 million.

Headlands Technologies LLC reduced its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 92.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 932 shares of the company's stock after selling 12,039 shares during the period. Headlands Technologies LLC's holdings in LivaNova were worth $37,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of LIVN. GAMMA Investing LLC boosted its stake in shares of LivaNova by 2,299.7% in the first quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock worth $344,000 after acquiring an additional 8,394 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of LivaNova in the fourth quarter worth approximately $2,772,000. Envestnet Asset Management Inc. boosted its stake in shares of LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after acquiring an additional 5,850 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in shares of LivaNova by 147.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock worth $4,582,000 after acquiring an additional 58,911 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its stake in shares of LivaNova by 148.5% in the fourth quarter. Two Sigma Advisers LP now owns 214,545 shares of the company's stock worth $9,936,000 after acquiring an additional 128,200 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Down 0.8%

Shares of LivaNova stock traded down $0.41 during trading hours on Monday, hitting $53.31. The company's stock had a trading volume of 133,663 shares, compared to its average volume of 708,833. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35. The firm has a fifty day moving average of $45.70 and a 200-day moving average of $42.81. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -13.71 and a beta of 0.92. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%. The business had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. During the same quarter in the prior year, the company posted $0.93 EPS. The company's quarterly revenue was up 10.6% on a year-over-year basis. Research analysts forecast that LivaNova PLC will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LIVN. Robert W. Baird lifted their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a research note on Tuesday, May 20th. Barclays lowered their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Finally, Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.